TNF and dermatomyositis: Exogenous synthetic cannabinoids represent a novel approach to modulating inflammation, as the activation of CB2R has been shown to reduce several key pro-inflammatory cytokines implicated in DM, including type I IFNs, IL-1, IL-6, IL-17, and TNF-α [15–19].